Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety

Pharmaceutical Research

Volumn 24, Issue 7, 2007, Pages 1309-1324

  Denora, Nunzio ^a   Laquintana, Valentino ^a   Lopedota, Angela ^a   Serra, Mariangela ^b   Dazzi, Laura ^b   Biggio, Giovanni ^b   Pal, Dhananjay ^c   Mitra, Ashim K ^c   Latrofa, Andrea ^a   Trapani, Giuseppe ^a   Liso, Gaetano ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Sezione di Neuroscienze   (Italy)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Blood brain barrier; Imidazopyridine compounds; L Dopa and dopamine; Microdialysis; Prodrugs

Indexed keywords

2 [2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; 2 [2 [6 CHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; 2 [2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2-A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; 2 [2 [6,8 DICHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOIC ACID; 2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DI TERT-BUTYLDIMETHYLSILYLOXYPHENYL)ETHYL]ACETAMIDE; 2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DIHYDROXYPHENYL)ETHYL]ACETAMIDE; 2 [6 CHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 Y] N [2 (3,4 DIHYDROXYPHENYL)ETHYL]ACETAMIDE; 2 [6 CHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DI TERT BUTYLDIMETHYLSILYLOXYPHENYL)ETHYL]ACETAMIDE; 2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 Y] N [2 (3,4 DIHYDROXYPHENYL)ETHYL]ACETAMIDE; 2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DI TERT BUTYLDIMETHYLSILYLOXYPHENYL)ETHYL]ACETAMIDE; 2 [6,8 DICHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DI TERT BUTYLDIMETHYLSILYLOXYPHENYL)ETHYL]ACETAMIDE; 2 [6,8 DICHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL] N [2 (3,4 DIHYDROXYPHENYL)ETHYL]ACETAMIDE; BENZODIAZEPINE RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR; DOPIMID COMPOUND; ETHYL 2 [2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOATE; ETHYL 2 [2 [6 CHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 [3,4 BIS(TERT BUTYLDIMETHYLSILYLOXY)PHENYL]PROPANOATE; ETHYL 2 [2 [6 CHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOATE; ETHYL 2 [2 [6 CHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 [3,4 BIS(TERT BUTYLDIMETHYLSILYLOXY)PHENYL] PROPANOATE; ETHYL 2 [2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOATE; ETHYL 2 [2 [6,8 DICHLORO 2 (4 CHLOROPHENYL)IMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 [3,4 BIS(TERT BUTYLDIMETHYLSILYLOXY)PHENYL]PROPANOATE; ETHYL 2 [2 [6,8 DICHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 (3,4 DIHYDROXYPHENYL)PROPANOATE; ETHYL 2 [2 [6,8 DICHLORO 2 PHENYLIMIDAZO[1,2 A]PYRIDIN 3 YL]ACETYLAMINO] 3 [3,4 BIS(TERT BUTYLDIMETHYLSILYLOXY)PHENYL]PROPANOATE; IMIDAZOPYRIDINE DERIVATIVE; LEVODOPA; PRODRUG; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; COW; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME SUBSTRATE; FEMALE; KIDNEY CELL; MALE; MICRODIALYSIS; MICROVASCULATURE; MULTIDRUG RESISTANCE; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CATTLE; CELL LINE; COMPUTER SIMULATION; DOGS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ENDOTHELIAL CELLS; FEASIBILITY STUDIES; IMIDAZOLES; INJECTIONS, INTRAPERITONEAL; LEVODOPA; MICRODIALYSIS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PREFRONTAL CORTEX; PRODRUGS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, GABA-A; RITONAVIR; TIME FACTORS; TRITIUM;

EID: 34249895912     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9255-y     Document Type: Article

References (34)

1. R. Bäckstrom, E. Honkanen, A. Pippuri, P. Kairisalo, J. Pystynen, K. Heinola, E. Nissinen, I. B. Linden, P. T. Männisto, S. Kaakkola, and P. Pohto. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem. 32:841-846 (1989).
2. A. Di Stefano, B. Mosciatti, G. M. Cingolani, G. Giorgioni, M. Ricciutelli, I. Cacciatore, P. Sozio, and F. Claudi. Dimeric L-Dopa derivatives as potential prodrugs. Biorg. Med. Chem. Lett. 11:1085-1088 (2001).
3. H. Wang, J. Lee, M. Tsai, H. Lu, and W. Hsu. Synthesis and pharmcological activities of a novel tripeptide mimetic dopamine prodrug. Biorg. Med. Chem. Lett. 5:2195-2198 (1995).
4. R. Pahwa and W. C. Koller. Advances in the treatment of Parkinson's disease. Drugs Today 34:95-105 (1998).
5. J. Jankovic and C. D. Marsden. Therapeutic strategies in Parkinson's disease. In J. Jankovic and E. Tolosa (eds.), Parkinson's Disease and Movement Disorders, Urban, Munich, 1988, pp. 95-119.
6. A receptors. J. Med. Chem. 45:4655-4688 (2002).
7. J. Benavides, B. Peny, D. Ruano, J. Vitorica, and B. Scatton. Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem. Brain Res. 604:240-250 (1993).
8. A. Durand, J. P. Thenot, G. Bianchetti, and P. L. Morselli. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24:239-266 (1992).
9. A. Daniele, A. Albanese, G. Gainotti, B. Gregari, and P. Bartolomeo. Zolpidem in Parkinson's disease. Lancet 349:1222-1223 (1997).
10. G. Trapani, V. Laquintana, A. Latrofa, J. Ma, K. Reed, M. Serra, G. Biggio, G. Liso, and J. M. Gallo. Peripheral benzodiazepine receptor ligand. Melphalan conjugates for potential selective drug delivery to brain tumors. Bioconjug. Chem. 14:830-839 (2003).
11. L. Nakonieczna, W. Przychodzen, and A. Chimiak. A new convenient route for the synthesis of DOPA peptides. Liebigs Ann. Chem. 1055-1058 (1994).
12. D. R. Cooper, C. Marrel, H. van de Waterbeemd, B. Testa, P. Jenner, and C. D. Marsden. L-Dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J. Pharm. Pharmacol. 39:627-635 (1987).
13. F. Tang, K. Horie, and R. T. Borchardt. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm. Res. 19:765-772 (2002).
14. D. E. Clark. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88:815-821 (1999).
15. P. Ertl, B. Rohde, and P. Selzer. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43:3714-3717 (2000).
16. K. L. Audus and R. T. Borchardt. Bovine brain microvessel endothelial cell monolayers as a model for blood-brain barrier. Ann. N.Y. Acad. Sci. USA 507:9-18 (1987).
17. D. Pal, K. L. Audus, and T. J. Siahaan. Modulation of cellular adhesión in bovine brain microvessel endotelial cells by a decapeptide. Brain Res. 747:103-113 (1997).
18. S. L. Glynn and M. Yazdanian. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87:306-310 (1998).
19. I. Megard, A. Garrigues, S. Orlowski, S. Jorajuria, P. Clayette, and E. Ezan, A. Mabondzo. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 927:153-157 (2002).
20. G. Paxinos and C. Watson. The rat brain in stereotaxic coordinates, Academic, London, 1982.
21. L. Dazzi, M. Serra, M. L. Porceddu, A. Sanna, M. F. Chessa, and G. Biggio. Enhancement of basal and pentylenetetrazol (PTZ)-stimulated dopamine release in the brain of freely moving rats by PTZ-induced kindling. Synapse 26:351-358 (1997).
22. M. D. Majewska, N. L. Harrison, R. D. Schwartz, J. L. Barker, and S. M. Paul. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232:1004-1007 (1986).
23. E. Giesen-Crouse. Peripheral benzodiazepine receptors, Academic Press, London, 1993.
24. G. Trapani, M. Franco, L. Ricciardi, A. Latrofa, G. Genchi, E. Sanna, F. Tuveri, E. Cagetti, G. Biggio, and G. Liso. Synthesis and binding affinity of 2-phenyl-imidazo[1,2-a]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type. J. Med. Chem. 40:3109-3118 (1997).
25. G. Trapani, M. Franco, A. Latrofa, L. Ricciardi, A. Carotti, M. Serra, E. Sanna, G. Biggio, and G. Liso. Novel 2-phenyl-imidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors. Synthesis, binding affinity, and in vivo studies. J. Med. Chem. 42:3934-3941 (1999).
26. G. Le Fur, M. L. Perrier, N. Vaucher, F. Imbant, A. Flamier, A. Uzan, C. Renault, M. C. Dubroeucq, and C. Gueremy. Peripheral binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 32:1839-1847 (1983).
27. A. Albert. Chemical aspects of selective toxicity. Nature 182:421-423 (1958).
28. A. Tsuji, T. Terasaki, Y. Takabatake, Y. Tenda, I. Tamai, T. Yamashima, S. Moritani, T. Tsuruo, and J. Yamashita. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427-1437 (1992).
29. M. Yamazaki, W. E. Neway, T. Ohe, I. Chen, J. F. Rowe, J. H. Hochman, M. Chiba, and J. H. Lin. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:723-735 (2001).
30. N. Bodor and P. Buchwald. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36:229-254 (1999).
31. U. Norinder and M. Haeberlein. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54:291-313 (2002).
32. M. V. Shah, K. L. Audus, and R. T. Borchardt. The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm. Res. 7:624-627 (1989).
33. J. B. Jr Justice. Quantitative microdialysis of neurotransmitters. J. Neurosci. Methods 48:263-276 (1993).
34. A. Eltayb, M.-L. G. Wademberg, and T. H. Svensson. Enhanced cortical dopamine output and antipsycotic-like effect of raclopride with adjunctive low-dose L-Dopa. Biol. Psychiatry 58:337-343 (2005).